A concern in breast cancer involves changes in weight which may adversely affect the prognosis of patients. This
study intended to evaluate weight changed uring chemotherapy and its association with prognostic outcome
measured as event-free survival (EFS)among breast cancer patients. A total of63 women diagnosed with breast cancer
and have been treated by anthracycline-based chemotherapy between 2005 and 2011were included.A weight change
(WC) was calculated based on relative percentage of weight changes from baseline to post-chemotherapy and
categorized into either weight change (WC >5%) or stable (±5% WC).Survival probabilities were estimated using the
Kaplan-Meier (SPSS 20). Upon treatment completion, 42.9% of the women experienced weight changes. A small
weight reduction was observed (61.1 ± 11.6kg to 60.2 ± 11.9kg; -0.8 ± 4.0kg; p=0.106). The median EFS of women who
experienced weight change was shorter (median 61.0 months) compared to those who maintained their weight
(median 89.0 months) (p=0.044). In this study, weight changes during breast cancer chemotherapy were associated
with poorer prognosis in comparison to women who maintained their weight.